DE69940975D1 - Verwendung von glp-1 oder analoge zur behandlung von schlaganfall - Google Patents

Verwendung von glp-1 oder analoge zur behandlung von schlaganfall

Info

Publication number
DE69940975D1
DE69940975D1 DE69940975T DE69940975T DE69940975D1 DE 69940975 D1 DE69940975 D1 DE 69940975D1 DE 69940975 T DE69940975 T DE 69940975T DE 69940975 T DE69940975 T DE 69940975T DE 69940975 D1 DE69940975 D1 DE 69940975D1
Authority
DE
Germany
Prior art keywords
glp
stroke
analog
treatment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940975T
Other languages
English (en)
Inventor
Suad Efendic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69940975D1 publication Critical patent/DE69940975D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Complex Calculations (AREA)
  • Mechanical Light Control Or Optical Switches (AREA)
DE69940975T 1998-09-24 1999-09-22 Verwendung von glp-1 oder analoge zur behandlung von schlaganfall Expired - Lifetime DE69940975D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10171998P 1998-09-24 1998-09-24
PCT/US1999/022026 WO2000016797A2 (en) 1998-09-24 1999-09-22 Use of glp-1 or analogs in treatment of stroke

Publications (1)

Publication Number Publication Date
DE69940975D1 true DE69940975D1 (de) 2009-07-23

Family

ID=22286048

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940975T Expired - Lifetime DE69940975D1 (de) 1998-09-24 1999-09-22 Verwendung von glp-1 oder analoge zur behandlung von schlaganfall

Country Status (12)

Country Link
EP (1) EP1115421B1 (de)
JP (1) JP2002526454A (de)
CN (1) CN1163267C (de)
AT (1) ATE433324T1 (de)
AU (1) AU766375B2 (de)
BR (1) BR9913932A (de)
CA (1) CA2344056A1 (de)
DE (1) DE69940975D1 (de)
ES (1) ES2325777T3 (de)
MY (1) MY155270A (de)
TW (1) TWI260986B (de)
WO (1) WO2000016797A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
WO2001085256A2 (en) * 2000-05-05 2001-11-15 Novo Nordisk A/S Critical illness neuropathy
KR100518046B1 (ko) 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
US20040235726A1 (en) * 2001-10-01 2004-11-25 Jakubowski Joseph Anthony Glucagon-like peptides (glp-1) and treatment of respiratory distress
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
NZ534125A (en) 2002-02-20 2006-11-30 Emisphere Tech Inc A formulation comprising a GLP-1 compound and a delivery agent
PT1641823E (pt) 2003-06-12 2011-11-08 Lilly Co Eli Proteínas de fusão de análogos de glp-1
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
EP1729795B1 (de) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albuminfusionsproteine
DE602006017202D1 (de) 2005-05-13 2010-11-11 Lilly Co Eli Pegylierte glp-1-verbindungen
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
JP5604297B2 (ja) 2008-06-17 2014-10-08 株式会社糖鎖工学研究所 糖鎖付加ｇｌｐ−１ペプチド
EP2216042A1 (de) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP1-analoge pharmazeutische Zusammensetzungen
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
EP2427204B1 (de) 2009-05-06 2017-04-05 Janssen Biotech, Inc. Melanocortinrezeptor-bindende konjugate
US20120264684A1 (en) 2009-10-30 2012-10-18 Yasuhiro Kajihara Glycosylated Form of Antigenic GLP-1 Analogue
EP2512518A1 (de) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1-rezeptoragonistverbindungen mit modifiziertem n-terminus
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
EP2637698B1 (de) * 2010-11-09 2022-04-20 Novo Nordisk A/S Zweifach acylierte glp-1-derivate
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX355361B (es) 2011-04-12 2018-04-17 Novo Nordisk As Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
MY171146A (en) 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP2863895B1 (de) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablettenformulierung enthaltend ein peptid und einen adsorptionsvermittler
CA2914773A1 (en) * 2013-06-07 2014-12-11 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
US10485870B2 (en) 2015-02-11 2019-11-26 Gmax Biopharm Llc. Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein
CN105254720B (zh) * 2015-11-18 2018-10-09 暨南大学 一种多受体激动剂po13及应用
WO2018113340A1 (zh) * 2016-12-20 2018-06-28 中国药科大学 多肽p11及其用途
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
JP2024500410A (ja) * 2020-12-16 2024-01-09 ザ チャイニーズ ユニバーシティー オブ ホンコン 老化脳機能低下を逆転する方法
CN116970062B (zh) * 2022-04-29 2024-04-09 南京知和医药科技有限公司 一种超长效glp-1多肽衍生物及其制备方法和用途
CN117836330A (zh) * 2022-06-23 2024-04-05 广州银诺医药集团股份有限公司 一种改进的glp-1受体激动剂的融合蛋白和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
DE122009000079I2 (de) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
EP1049486A4 (de) * 1997-12-05 2006-01-04 Lilly Co Eli Glp-1 formulierungen

Also Published As

Publication number Publication date
CA2344056A1 (en) 2000-03-30
MY155270A (en) 2015-09-30
CN1322137A (zh) 2001-11-14
AU6398599A (en) 2000-04-10
EP1115421B1 (de) 2009-06-10
ES2325777T3 (es) 2009-09-16
JP2002526454A (ja) 2002-08-20
AU766375B2 (en) 2003-10-16
EP1115421A2 (de) 2001-07-18
CN1163267C (zh) 2004-08-25
WO2000016797A3 (en) 2000-05-25
WO2000016797A2 (en) 2000-03-30
ATE433324T1 (de) 2009-06-15
TWI260986B (en) 2006-09-01
BR9913932A (pt) 2001-10-16

Similar Documents

Publication Publication Date Title
DE69940975D1 (de) Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
EA200001175A1 (ru) Бензотиофены, бензофураны и индолы, полезные в лечении устойчивости к инсулину и гипергликемии
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
ATE289508T1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
ATE205401T1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
DE69814394D1 (de) Verwendung von levobupivacain
DE3686582D1 (de) Behandlung einer krankheit vom aids-typ.
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE201598T1 (de) Verwendung von moxonidin zur behandlung neuropathischer schmerzen
ATE293972T1 (de) Behandlung von chronischen schmerzen
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
EA199900006A1 (ru) Препарат и способ для лечения застоной сердечной недостаточности
UA23921A (uk) Спосіб лікування шлунково-стравохідного рефлюксу
EA199800818A1 (ru) Способ лечения бессонницы
RU2001132695A (ru) Способ лечения поздних лучевых повреждений кожи и подкожной клетчатки

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN